Sarah E. Bohndiek1,2, Mikko I. Kettunen1,2,
De-en Hu1,2, Timothy H. Witney1,2, Ferdia A. Gallagher1,2,
Kevin M. Brindle1,2
1Department of Biochemistry, University
of Cambridge, Cambridge, Cambridgeshire, United Kingdom; 2Cancer
Research UK Cambridge Research Institute, Cambridge, Cambridgeshire, United
dramatically increases the sensitivity of the 13C magnetic resonance
experiment, allowing the uptake and metabolism of hyperpolarized substrates
to be followed in vivo. Vascular disrupting agents target the proliferating
endothelial cells in tumour vasculature, so rarely cause tumour shrinkage.
Our aim was to assess whether hyperpolarized [1-13C]pyruvate and
[1,4-13C]fumarate magnetic resonance spectroscopy could detect response to
treatment with Combretastatin-A4-Phosphate within 24 hours of treatment and
to compare these methods with data obtained by Dynamic Contrast Enhanced MRI
(using Gd-DTPA) and Diffusion Weighted Imaging.